Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC) (MERECA)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02432846 |
|
Recruitment Status :
Completed
First Posted : May 4, 2015
Results First Posted : August 22, 2022
Last Update Posted : August 22, 2022
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Renal Cell Carcinoma, Metastatic | Biological: Intuvax (INN: ilixadencel) Drug: Sunitinib | Phase 2 |
Patients, all planned for nephrectomy, will be stratified according to the Heng risk criteria (high risk patients vs. intermediate risk patients) and randomized in a 2:1 ratio to receive Intuvax (INN: ilixadencel)+ Sunitinib or Sunitinib alone.
Two doses of Intuvax (INN: ilixadencel) will be administered in to the primary tumour before nephrectomy. The control group will be scheduled for nephrectomy directly.
All patients will start Sunitinib treatment 5-8 weeks after operation.
Results from the phase I study, together with the results reported in the literature on the use of autologous dendritic cells (DCs) in combination with Sunitinib encourage Immunicum aktiebolag (AB) to further investigate the possibility of exploiting Intuvax (INN: ilixadencel) 10 million cells/dose when combined with Sunitinib for the treatment of mRCC patients.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 88 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | An Open-label, Randomized, Controlled, Multicenter, Phase II Study Evaluating Safety and Efficacy of Intratumorally Administered Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy, Compared to Sunitinib Post-nephrectomy in Metastatic Renal Cell Carcinoma Patients |
| Study Start Date : | April 2015 |
| Actual Primary Completion Date : | January 31, 2021 |
| Actual Study Completion Date : | January 31, 2021 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Intuvax (INN: ilixadencel)+ Nephrectomy+Sunitinib
Two Intuvax (INN: ilixadencel) doses (10 million cells/dose) 14 days apart before nephrectomy, followed by Sunitinib treatment post-nephrectomy according to clinical practice until RECIST verified progressive disease or End-of-Study (78 weeks after screening).
|
Biological: Intuvax (INN: ilixadencel)
Therapeutic dose (10 million cells/dose): allogeneic, pro-inflammatory dendritic cells.
Other Name: COMBIG-DC Drug: Sunitinib Cytostatic/cytotoxic drug: protein kinase inhibitor .
Other Name: Sutent |
|
Active Comparator: Nephrectomy+Sunitinib
Sunitinib treatment post-nephrectomy according to clinical practice until RECIST verified progressive disease or End-of-Study (78 weeks after screening).
|
Drug: Sunitinib
Cytostatic/cytotoxic drug: protein kinase inhibitor .
Other Name: Sutent |
- Overall Survival (OS) - Days (FAS) [ Time Frame: From the randomization to the date of death, up to 5 years after the last participant's 18-month survival data. ]
OS is the time from randomization until date of death. The patients who were alive at the end of study were followed for survival status (alive/date of death) through medical records, databases and public records according to the time frame below.
Due to censored data, estimates of upper 95% CI could not be determined in all reporting groups.
- Overall Survival - Days (PPS) [ Time Frame: From the randomization to the date of death, up to 5 years after the last patient's 18-month survival data. ]
OS is the time from randomization until date of death. The patients who were alive at the end of study were followed for survival status (alive/date of death) through medical records, databases and public records according to the time frame below.
Due to censored data, upper 95% CI could not be determined in all reporting groups.
- 18-Months' Overall Survival Percentage (FAS) [ Time Frame: At 18 months (544 days) ]The 18-month survival percentage was defined as the percentage of patients alive 18 months after randomization.
- 18-Months' Overall Survival Percentage (PPS) [ Time Frame: At 18 months (544 days) ]The 18-month survival percentage was defined as the percentage of patients alive 18 months after randomization.
- Progression Free Survival (PFS) From Start of Sunitinib According to RECIST 1.1. [ Time Frame: From Sunitinib-Start to progressive disease or death, up to 18 months. ]
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by radiographic assessment: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Due to the large amount of censored data, estimates of median and/or a 95% CI could not be reliably determined in all reporting groups.
Baseline data are reported for the safety data set (all patients randomized) whereas PFS is analyzed for the full analysis set (FAS). Two patients in the safety data set were not included in the FAS since they withdrew prior to start of treatment.
- Objective Response Rate (ORR) From Start of Sunitinib Treatment and Duration of Response in Each Subgroup. [ Time Frame: From start of sunitinib treatment up to 18 months ]Objective response rate was defined as the percentage of patients with complete response (CR) and partial response (PR).Tumor response was evaluated centrally according to the RECIST 1.1 guideline.
- Number of Participants With Specific Best Overall Response [ Time Frame: From start of sunitinib treatment up to 18 months ]The best overall response is the best response recorded from the start of the treatment sunitinib until disease progression/recurrence; taking as reference for progressive disease (PD) the smallest measurements recorded since the treatment started. In general, the patient's best response assignment depended on the achievement of the measurement criteria.
- Disease Control Rate [ Time Frame: From start of sunitinib treatment up to 18 months ]Best overall response (CR, PR or SD) evaluated from Sunitinib-Start for patients with available data.
- Duration of Response [ Time Frame: From first date of CR or PR until date of PD or death, up to 18 months. ]The duration of response was calculated for only those patients who responded. It was the time from first objective response to first observed progression of disease or death if the death was due to disease progression (whichever came first).
- Duration of Clinical Benefit [ Time Frame: From first date of clinical benefit (CR, PR or SD) until date of PD or death, up to 18 months. ]Disease control rate (DCR) also called Clinical Benefit Rate, was defined as the proportion of patients with CR or PR or SD.
- Duration of Stable Disease [ Time Frame: From first date of SD until PD or date of death, up to 18 months. ]The duration of SD was calculated for only those patients who exhibited a best response of SD response as per RECIST v1.1. It was the time from first SD response to first observed progression of disease or death if the death was due to disease progression (whichever came first), up to 18 months.
- Time to Progression (TTP) [ Time Frame: Time from Sunitinib-Start to date of either PD according to RECIST 1.1 or clinical progression as evaluated by the Investigator, up to 18 months. ]Due to the large amount of censored data, estimate of upper 95% CI could not be reliably determined in all reporting groups.
- Percentage of Tumor Area With Infiltrating Cluster of Differentiation 8+ (CD8+) T-cells [ Time Frame: At resection of primary tumor. ]Relative number of tumor-infiltrating CD8+ T-cells in the resected primary tumor compared to number of infiltrating CD8+ T-cells in available diagnostic pre-biopsy (sample from either primary tumor or metastasis), was not to be evaluated as described in the protocol due to missing pre-biopsy samples). Instead an automated and validated quantification of percentage of CD8+ tissue in delineated tumor area was made.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Newly (<6 months) diagnosed RCC (histological/cytological verification is optional) with at least one (1) CT-verified metastasis ≥10mm for which complete metastasectomy is not planned. US patients must have verified clear-cell tumor histology
- Planned resection of primary tumor
- Primary tumor diameter ≥40 mm
- Candidate for first-line therapy with sunitinib initiated 5-8 weeks after nephrectomy
- Female or male ≥18 years of age
- Willing and able to provide informed consent
-
Adequate hematological parameters, i.e:
- B-Leukocyte count ≥4.5 x10e9/L
- B-Platelet count ≥150 x10e9/L
- B-Hemoglobin ≥90 g/L
- S-creatinine and S-bilirubin ≤ 1.5 x upper limit of normal (ULN). Serum alanine aminotransferase (S-ALAT) and serum aspartate aminotransferase (S-ASAT) ≤ 2.5 x ULN (or ≤5 in case of liver metastases)
- Female who has been post-menopausal for more than one (1) year or female of childbearing potential agreeing to use a highly efficient method of contraception (i.e. a method with less than 1% failure rate [e.g. sterilization, hormone implants, hormone injections, some intrauterine devices, or vasectomized partner or combined birth control pills]) Female of childbearing potential must have a negative from Screening until 90 days after last dose of Intuvax and/or until completed sunitinib treatment whichever occurs later.blood pregnancy test at Screening, and if randomized to vaccination a negative blood or urine pregnancy test within one (1) day before each dose of Intuvax) and must not be lactating.
or Male agreeing to use condoms from Screening until 90 days after last dose of Intuvax and/or until completed sunitinib treatment whichever occurs later, or male having a female partner who is using a highly efficient method of contraception as described above.
Exclusion Criteria:
- Life expectancy less than 4 months
- Central nervous system (CNS) metastasis that is symptomatic or progressing or untreated or that required current therapy (e.g. evidence of new or enlarging CNS metastasis or new neurological symptoms attributable to CNS metastases)
- Active autoimmune disease which requires treatment with systemic immunosuppressive agents, e.g. inflammatory bowel disease, multiple sclerosis, sarcoidosis, psoriasis, autoimmune hemolytic anemia, rheumatoid arthritis, systemic lupus erythematosus (SLE), vasculitis, Sjögren's syndrome, scleroderma, autoimmune hepatitis, and other rheumatological diseases
- Treatment with per oral systemic corticosteroids exceeding 10mg/day within seven (7) days before Screening until nephrectomy (inhaled, intranasal and local steroids accepted irrespective of dose)
- Known cardiomyopathy and/or clinical significant abnormal ECG findings at Screening disqualifying the patient from nephrectomy and from subsequent sunitinib treatment
- Karnofsky performance status <70%
- National Cancer Institute (NCI) Common Terminology criteria for Adverse Events (CTCAE) Grade 3 hemorrhage within 28 days before Screening
- Pre-existing thyroid abnormality with thyroid function that cannot be maintained in the normal range with medication
- Clinically significant gastrointestinal abnormalities
- Uncontrolled hypertension, or uncontrolled diabetes mellitus
- Pulmonary embolism within 12 months before screening
- Prior history of invasive cancer within 5 years before screening, except for adequately treated in situ carcinomas or non-melanoma skin cancer
- Ongoing infection that requires parenteral treatment with antibiotics
- Active or latent virus disease (HIV, hepatitis B and hepatitis C)
- Eastern Cooperative Oncology Group (ECOG) performance status >2 after optimization of analgesics
-
Abnormal and clinical significant coagulation parameters at the discretion of the Investigator, i.e.:
- Prothrombin Time - International Normalized Ratio (PT-INR)
- Activated Partial Thromboplastin Time (APTT) patients being treated with anticoagulants are excluded if the coagulation parameters are outside the therapeutic intervals as described in the summary of product characteristics (SmPC) / United States prescribing information (USPI) for the administered treatment
- Known major adverse reaction/event in connection with previously made vaccination (e.g. asthma, anaphylaxis or other serious reaction)
- Known hypersensitivity or allergy sunitinib or to chemically related products or likely to be exacerbated to by any component of the study products
- Prior systemic antitumour therapy within 28 days before Screening Visit. However, local radiation therapy to any area except for the abdominal/retroperitoneal area including the kidney tumour is allowed
- Exposure to other investigational products within 28 days prior to Screening Visit
- patients on anticoagulants for whom temporarily stop and start, supported by low molecular weight heparin (or other anticoagulation therapy at the discretion of the investigator and or per local standard of care) during vaccination and nephrectomy, is not an option
- History of alcohol or substance abuse
- Any reason that, in the opinion of the Investigator, contraindicates that the patient participates in the study
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02432846
Show 28 study locations
| Principal Investigator: | Börje Ljungberg, MD, Prof | Umeå University Hospital |
Documents provided by Mendus:
| Responsible Party: | Mendus |
| ClinicalTrials.gov Identifier: | NCT02432846 |
| Other Study ID Numbers: |
IM-201 2014-004510-28 ( EudraCT Number ) |
| First Posted: | May 4, 2015 Key Record Dates |
| Results First Posted: | August 22, 2022 |
| Last Update Posted: | August 22, 2022 |
| Last Verified: | July 2022 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Carcinoma Carcinoma, Renal Cell Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Adenocarcinoma Kidney Neoplasms Urologic Neoplasms Urogenital Neoplasms Neoplasms by Site Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Urogenital Diseases |
Kidney Diseases Urologic Diseases Male Urogenital Diseases Sunitinib Antineoplastic Agents Angiogenesis Inhibitors Angiogenesis Modulating Agents Growth Substances Physiological Effects of Drugs Growth Inhibitors Protein Kinase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |